Biopure Down 35% On FDA Rejection of Blood Substitute Trial
by H.S. Ayoub
BioHealth Investor
Shares of Blood Substitute developer Biopure Corporation (BPUR) were down by as much as 35% in pre-market action on Friday following an announcement by the company that its proposed phase III trial of Hemopure by the Navy.
The Navy was planning on conducting a 100 patient phase IIb/III trial of Hemopure as a blood substitute for hemorrhagic shock treatment during pre-hospital care.
The FDA's Blood Products Advisory Committee voted 11 to 8 in favor of rejecting the proposed new trial, and recommended a new phase II trial instead.
Shares of Biopure were down $0.38 in pre-market trading. Shares closed at $0.589 on Thursday, and reached a 52-high of $1.53 back in March.
__
Similar BHI articles:
- New Commissioner Needs to Restore FDA Image
- FDA Asks Acorda to Conduct Another Phase III Trial
__
BioHealth Investor
Shares of Blood Substitute developer Biopure Corporation (BPUR) were down by as much as 35% in pre-market action on Friday following an announcement by the company that its proposed phase III trial of Hemopure by the Navy.The Navy was planning on conducting a 100 patient phase IIb/III trial of Hemopure as a blood substitute for hemorrhagic shock treatment during pre-hospital care.
The FDA's Blood Products Advisory Committee voted 11 to 8 in favor of rejecting the proposed new trial, and recommended a new phase II trial instead.
Shares of Biopure were down $0.38 in pre-market trading. Shares closed at $0.589 on Thursday, and reached a 52-high of $1.53 back in March.
__
Similar BHI articles:
- New Commissioner Needs to Restore FDA Image
- FDA Asks Acorda to Conduct Another Phase III Trial
__
posted by Nico at
8:49 AM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home